Updates on the Management of Immunotherapy-Related Toxicities

Presented by:
Marianne Davies
Search for other papers by Marianne Davies in
Current site
Google Scholar
PubMed
Close
 DNP, MSN, RN, ACNP-BC, AOCNP
,
Jordan McPherson
Search for other papers by Jordan McPherson in
Current site
Google Scholar
PubMed
Close
 PharmD, MS, BCOP
, and
John A. Thompson
Search for other papers by John A. Thompson in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

With the increased use of immune checkpoint inhibition (ICI) comes an increase in the number of patients being treated for immune-related adverse events (irAEs). At the NCCN 2023 Annual Conference, presenters discussed 3 different types of irAEs, namely immune-mediated pneumonitis, major adverse cardiac events including myocarditis and myositis/myasthenia gravis overlap syndrome, and oral toxicities including mucositis and sicca syndrome. They emphasized the importance of considering comorbidities and infectious causes when treating immune pneumonitis. In the context of cardiac events during ICI therapy, the presentation highlighted the need for early detection and vigilance in recognizing insidious, nonspecific symptoms, particularly in cases involving myocarditis with myositis/myasthenia gravis overlap syndrome. Finally, the increasing recognition of oral toxicities was discussed, in addition to the importance of timely intervention to prevent long-term morbidity.

Disclosures: Dr. Davies has disclosed no relevant financial relationships. Dr. McPherson has disclosed receiving grant/research support from Hitachi, Ltd. Dr. Thompson has disclosed serving as a scientific advisor for Bristol Myers Squibb Company and MabQuest SA.

Correspondence: Marianne Davies, DNP, MSN, RN, ACNP-BC, AOCNP, Yale Cancer Center, 333 Cedar Street, New Haven, CT 06511. Email: marianne.davies@yale.edu;

Jordan McPherson, PharmD, MS, BCOP, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT 84112. Email: jordan.mcpherson@hci.utah.edu; and

John A. Thompson, MD, Fred Hutchinson Cancer Research Center, 825 Eastlake Avenue East, Mailstop LG-350, Seattle, WA 98105. Email: jat@uw.edu
  • Collapse
  • Expand
  • 1.

    Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities. Ann Oncol 2016;27:559574.

  • 2.

    Naqash AR, Moey MYY, Cherie Tan XW, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the NCI-CTEP. J Clin Oncol 2022;40:34393452.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020;9:e013757.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Pathak R, Katel A, Massarelli E, et al. Immune checkpoint inhibitor- induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 2021;26:10521061.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 1.2023. Accessed April 14, 2023. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1876 1132 62
PDF Downloads 1445 828 69
EPUB Downloads 0 0 0